AnswersPublished32 sources
Ivonescimab Beats Keytruda on Survival in China
In China’s Phase 3 HARMONi 2 trial, ivonescimab significantly improved overall survival versus pembrolizumab after nearly doubling median progression free survival (11.14 vs 5.82 months; HR 0.51) in PD L1 positive adv... The widely cited 0.76 overall survival hazard ratio in Western patients came from a different gl...
Published byEdited with GPT-5.6 TerraImages generated with GPT Image 2
Research answer
Key takeaways
- In China’s Phase 3 HARMONi 2 trial, ivonescimab significantly improved overall survival versus pembrolizumab after nearly doubling median progression free survival (11.14 vs 5.82 months; HR 0.51) in PD L1 positive adv...
- The widely cited 0.76 overall survival hazard ratio in Western patients came from a different global trial in previously treated EGFR mutated non squamous NSCLC—not from a Keytruda head to head trial—and the analysis...
- China has authorized three ivonescimab containing NSCLC indications. The next tests of international relevance are HARMONi 3, which combines ivonescimab with chemotherapy, and HARMONi 7, a global monotherapy compariso...
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: How did Akeso and Summit Therapeutics’ PD-1/VEGF bispecific antibody ivonescimab become the first treatment to significantly outperform pemb. Article summary: Ivonescimab’s China data now establish a compelling proof of concept for simultaneously blocking PD-1 and VEGF, but they do not yet prove that the monotherapy benefit over Keytruda will reproduce in Western first-line NS. Topic tags: general, general web, user generated, news. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts w
Ivonescimab has produced the most consequential China-only challenge yet to pembrolizumab in first-line non-small cell lung cancer (NSCLC). In the randomized, double-blind Phase 3 HARMONi-2 trial, the PD-1/VEGF bispecific antibody improved progression-free survival and subsequently met the trial’s key secondary overall-survival endpoint against pembrolizumab monotherapy in PD-L1-positive locally advanced or metastatic disease. 39
42
That is an important clinical signal—but it is not yet evidence that ivonescimab can displace Keytruda in Western practice. The survival result needs full disclosure and international replication.
What HARMONi-2 showed
HARMONi-2 compared ivonescimab monotherapy with pembrolizumab monotherapy in previously untreated, PD-L1-positive advanced NSCLC in China. At the primary analysis, independently reviewed median progression-free survival was 11.14 months with ivonescimab versus 5.82 months with pembrolizumab, for a hazard ratio of 0.51 (95% CI, 0.38–0.69; p<0.0001). 39
42
On September 2, 2026, Akeso reported that a prespecified interim overall-survival analysis, assessed by the independent data monitoring committee, met the key secondary endpoint and showed a statistically significant benefit over pembrolizumab. The detailed overall-survival figures were not yet publicly released, so the magnitude and durability of the survival difference cannot yet be independently assessed from the announcement alone. 24
35
36
Why the result matters
Ivonescimab is designed to target both PD-1 and VEGF in one antibody. HARMONi-2 is therefore a direct test of whether this dual-target strategy can improve upon PD-1 blockade alone in a first-line, biomarker-selected population.
The trial’s sequence of results matters: a large progression-free-survival advantage was followed by a statistically significant overall-survival finding. Overall survival is generally the harder endpoint to improve because it measures time to death and can be influenced by therapies patients receive after the study treatment. Still, the available public disclosure does not yet provide the survival median, hazard ratio, confidence interval, or full safety update needed to judge the complete clinical trade-off. 35
36
Ivonescimab’s three China NSCLC approvals
China’s National Medical Products Administration has authorized three ivonescimab-containing NSCLC uses:
- First-line PD-L1-positive advanced NSCLC: ivonescimab monotherapy, supported by HARMONi-2.
40
41
- Previously treated EGFR-mutated, non-squamous NSCLC: ivonescimab plus chemotherapy after EGFR-TKI resistance.
25
29
- First-line advanced squamous NSCLC: ivonescimab plus chemotherapy, authorized in August 2026 following HARMONi-6.
18
The third authorization was based on HARMONi-6, a randomized Phase 3 China trial in previously untreated advanced squamous NSCLC. It compared ivonescimab plus platinum-based chemotherapy with tislelizumab plus chemotherapy. The reported interim overall-survival result favored the ivonescimab regimen: median overall survival was 27.9 months versus 23.7 months, with a hazard ratio of 0.66 (95% CI, 0.50–0.87). 19
27
28
HARMONi-6 is supportive evidence for the broader PD-1/VEGF approach, but it is not a pembrolizumab comparison and it studied a different regimen and NSCLC subtype than HARMONi-2.
The key limitation: China results are not global confirmation
Both HARMONi-2 and HARMONi-6 were conducted in China. Their results establish a strong rationale to test ivonescimab more broadly, but they do not by themselves demonstrate equivalent benefit in international first-line populations.
The relevant global confirmation work is still underway. HARMONi-3 compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line metastatic squamous and non-squamous NSCLC, regardless of PD-L1 expression. An early interim analysis in the squamous cohort did not cross its efficacy threshold; blinded follow-up continued. Final progression-free-survival events for that cohort were expected in the second half of 2026, alongside planned interim overall-survival analyses. The non-squamous cohort’s progression-free-survival events were expected in the first half of 2027. 4
43
47
That interim outcome is not a final verdict on HARMONi-3. But it means the China results have not yet been reproduced in the global first-line program most relevant to chemo-immunotherapy practice.
Why the Western OS hazard ratio of 0.76 needs context
A frequently cited 0.76 overall-survival hazard ratio in Western patients does not come from HARMONi-2 or HARMONi-3. It comes from the separate global Phase 3 HARMONi study in patients with EGFR-mutated, non-squamous advanced NSCLC whose disease progressed after a third-generation EGFR tyrosine kinase inhibitor.
That study compared ivonescimab plus platinum-doublet chemotherapy with placebo plus chemotherapy—not with pembrolizumab. At the prespecified primary overall-survival analysis, the result showed a favorable trend but did not reach statistical significance: hazard ratio 0.79 (95% CI, 0.62–1.01; p=0.057). 2
12
With later follow-up, Summit reported an overall-survival hazard ratio of 0.76 in both the overall intention-to-treat population and the Western subgroup. The Western subgroup included 165 patients, and the update was described as a favorable, non-statistically significant trend. It is encouraging supportive evidence, but it is not confirmatory proof that ivonescimab improves survival in Western patients against Keytruda. 6
8
What comes next
Three near-term milestones will determine how far these findings travel beyond China:
- HARMONi-3: Final progression-free-survival analysis for the global squamous cohort was anticipated in the second half of 2026, with interim overall-survival analyses planned.
43
- FDA review in EGFR-mutated NSCLC: The FDA accepted Summit’s biologics license application for ivonescimab plus chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. The stated PDUFA goal date is November 14, 2026.
- HARMONi-7: This global, randomized, double-blind Phase 3 trial is the cleanest test of the HARMONi-2 question outside China: ivonescimab monotherapy versus pembrolizumab monotherapy in first-line metastatic NSCLC with high PD-L1 expression. It is designed to enroll about 780 patients.
Bottom line
HARMONi-2 makes ivonescimab a serious PD-1/VEGF contender: it nearly doubled median progression-free survival and has now reported a statistically significant overall-survival advantage over pembrolizumab in its Chinese study population. 39
42
The appropriate conclusion is narrower than a global Keytruda replacement claim. The complete survival data need publication, and HARMONi-3 and especially HARMONi-7 must show whether the benefit holds in international populations and against pembrolizumab-based standards of care.
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "Ivonescimab Beats Keytruda on Survival in China"?
In China’s Phase 3 HARMONi 2 trial, ivonescimab significantly improved overall survival versus pembrolizumab after nearly doubling median progression free survival (11.14 vs 5.82 months; HR 0.51) in PD L1 positive adv...
What are the key points to validate first?
In China’s Phase 3 HARMONi 2 trial, ivonescimab significantly improved overall survival versus pembrolizumab after nearly doubling median progression free survival (11.14 vs 5.82 months; HR 0.51) in PD L1 positive adv... The widely cited 0.76 overall survival hazard ratio in Western patients came from a different global trial in previously treated EGFR mutated non squamous NSCLC—not from a Keytruda head to head trial—and the analysis...
What should I do next in practice?
China has authorized three ivonescimab containing NSCLC indications. The next tests of international relevance are HARMONi 3, which combines ivonescimab with chemotherapy, and HARMONi 7, a global monotherapy compariso...
Sources
prnewswire.comIvonescimab Shows Quality of Life Benefits in ...
tradingkey.comIvonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC